Frankfurt - Delayed Quote EUR

Novonesis A/S (NZM.F)

60.00

+2.00

+(3.45%)

At close: May 16 at 9:30:45 PM GMT+2

Is Novozymes (NVZMY) Stock Outpacing Its Basic Materials Peers This Year?

Here is how Novozymes A/S (NVZMY) and Mosaic (MOS) have performed compared to their sector so far this year.

Zacks 2 days ago

NVZMY
Best Income Stocks to Buy for May 14th

SWX, FTS and NVZMY made it to the Zacks Rank #1 (Strong Buy) income stocks list on May 14, 2025.

Zacks 3 days ago

SWX

NVZMY
New Strong Buy Stocks for May 14th

BTSG, NVZMY, SWX, FTS and ULS have been added to the Zacks Rank #1 (Strong Buy) List on May 14, 2025.

Zacks 3 days ago

BTSG

NVZMY

ULS
All You Need to Know About Novozymes (NVZMY) Rating Upgrade to Strong Buy

Novozymes (NVZMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 8 days ago

NVZMY
Novonesis (Novozymes) B (NVZMF) Q1 2025 Earnings Call Highlights: Strong Organic Growth and ...

Novonesis (Novozymes) B (NVZMF) reports robust Q1 2025 results with 11% organic sales growth, driven by innovation and emerging market penetration.

GuruFocus.com 8 days ago

NVZMY
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook

COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter. Ester Baiget, President & CE

GlobeNewswire 9 days ago

NVZMF

NVZMY
Interim report Q1 2025

Strong start to the year and confirmed full-year outlook Ester Baiget, President & CEO: “We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. Growth was driven by strong innovation especially in emerging markets, and with a continued broad pull for our solutions in developed markets. Synergies are materializing as expected and we are confirming the full-year outlook. We continue to see solid demand across the business, and our

GlobeNewswire 9 days ago

NVZMF

NVZMY
Is Idaho Strategic Resources (IDR) Outperforming Other Basic Materials Stocks This Year?

Here is how Idaho Strategic Resources, Inc. (IDR) and Novozymes A/S (NVZMY) have performed compared to their sector so far this year.

Zacks last month

NVZMY
Resolutions from the Annual General Meeting 2025

Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2024Approval of distribution of profit with payment of an ordinary dividend of DKK 4.20 (corresponding to approximately EUR 0.56) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.00 (EUR ~0.27) was disbursed on September 3, 2024.Approval of the Remuneration Report for 2024 (advisory vote)Approval of the

GlobeNewswire last month

NVZMF

NVZMY
Are Basic Materials Stocks Lagging AngloGold Ashanti PLC (AU) This Year?

Here is how AngloGold Ashanti (AU) and Novozymes A/S (NVZMY) have performed compared to their sector so far this year.

Zacks last month

AU

NVZMY
Election of employee representatives to the Board of Directors

The employees have conducted the election of employee representatives to the Board of Directors of Novonesis (Novozymes A/S). The following employee representatives (in alphabetical order after surname) were elected for the next four years: Robert Nøddeskov Jensen, Senior Operator - newly electedLars Bo Køppler, Technician - newly electedPreben Nielsen, Science Manager – re-electedFrederikke Rose Spenner, Production Engineer - newly elected As alternates to the employee representatives to the Bo

GlobeNewswire 2 months ago

NVZMF

NVZMY
Initiation of share buyback program

On March 5, 2025, Novonesis will initiate a share buyback program as announced in Company Announcement No. 3 of February 26, 2025. Under the program, Novonesis will buy back B shares worth up to EUR 100 million in total during the remainder of 2025, corresponding to around 1.7 million B shares at the current share price. The program is contingent upon no major strategic initiatives being decided upon that will require a significant amount of capital. The shares acquired in the program will be us

GlobeNewswire 2 months ago

NVZMF

NVZMY
AXTA or NVZMY: Which Is the Better Value Stock Right Now?

AXTA vs. NVZMY: Which Stock Is the Better Value Option?

Zacks 2 months ago

NVZMY

AXTA
Novonesis (Novozymes) B (NVZMF) (Q4 2024) Earnings Call Highlights: Strong Organic Sales Growth ...

Novonesis reports an 8% organic sales growth for 2024, driven by innovation and sustainability, despite challenges in specific markets.

GuruFocus.com 2 months ago

NVZMY
12M 2024: Novonesis delivers strong full-year results and expects continued growth in 2025

Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of 37-38%. COPENHAGEN, Denmark – February 26, 2025. In the 2024 financial year, Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin at 36.1%. The sales growth is driven by both Food & Health Biosolutions and Planetary Health Biosolutions. Volumes have increased by ~6% with pricing cont

GlobeNewswire 2 months ago

NVZMF

NVZMY
12M 2024 Company announcement

2024 organic pro forma sales growth of 8%, with pro forma adjusted EBITDA margin of 36.1%. 2025 outlook of 5-8% organic pro forma sales growth and 37-38% adjusted EBITDA margin. 2024 organic pro forma sales growth of 8% (Q4: 7%) and 8% on IFRS reported basis (Q4 7%). Food & Health Biosolutions at 7%, and Planetary Health Biosolutions at 9%.2024 pro forma adjusted EBITDA margin of 36.1% (2H 36.8%), with 35.2% for Food & Health Biosolutions and 36.8% for Planetary Health Biosolutions. 2024 adjuste

GlobeNewswire 2 months ago

NVZMF

NVZMY
Change to the Executive Leadership Team

Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Ester Baiget, President & CEO comments: “I want to thank Jacob for his strong leadership and commitment to Novonesis and our Food & Beverage Biosolutions business. Jacob has played an instrumental role in Novonesis. As a result of his contribution, the Food & Beverage Biosolutions business in Novonesis rests on a

GlobeNewswire 2 months ago

NVZMF

NVZMY
Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance

Novonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities, in exchange for a total cash consideration of EUR 1.5 billion. After more than 25 years of successful collaboration, a strategic repositioning at dsm-firmenich allowed this opportunity to materialize. This acquisition is aligned with Novonesis’ growth strategy and expands its presence across the animal biosolutions value chain. Financially, this transact

GlobeNewswire 3 months ago

NVZMF

NVZMY
Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8%

Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%. COPENHAGEN, Denmark – November 7, 2024. Novonesis delivers 9% organic sales growth, in the first nine months of the 2

GlobeNewswire 6 months ago

NVZMF

NVZMY
Trading statement 9M 2024

Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5%. Ester Baiget, President & CEO: “We continue to execute strongly across the business. Supportive, broad-based demand coupled with strong innovation and commercial focus drive higher market penetration. Novonesis’ biosolutions are increasingly requested by customers to make their

GlobeNewswire 6 months ago

NVZMF

NVZMY

Performance Overview

Return	NZM.F	OMX Copenhagen 25 Index (^OMXC25)
YTD	+12.38%	--
1-Year	+8.90%	-12.18%
3-Year	+9.49%	+8.84%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novonesis A/S (NZM.F)

Is Novozymes (NVZMY) Stock Outpacing Its Basic Materials Peers This Year?

Best Income Stocks to Buy for May 14th

New Strong Buy Stocks for May 14th

All You Need to Know About Novozymes (NVZMY) Rating Upgrade to Strong Buy

Novonesis (Novozymes) B (NVZMF) Q1 2025 Earnings Call Highlights: Strong Organic Growth and ...

Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook

Interim report Q1 2025

Is Idaho Strategic Resources (IDR) Outperforming Other Basic Materials Stocks This Year?

Resolutions from the Annual General Meeting 2025

Are Basic Materials Stocks Lagging AngloGold Ashanti PLC (AU) This Year?

Election of employee representatives to the Board of Directors

Initiation of share buyback program

AXTA or NVZMY: Which Is the Better Value Stock Right Now?

Novonesis (Novozymes) B (NVZMF) (Q4 2024) Earnings Call Highlights: Strong Organic Sales Growth ...

12M 2024: Novonesis delivers strong full-year results and expects continued growth in 2025

12M 2024 Company announcement

Change to the Executive Leadership Team

Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance

Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8%

Trading statement 9M 2024

Performance Overview